// App-Quantinova.ai

TPS9600 : Intralesional rose bengal for treatment of melanoma.

Researchers

Presenter

  • Sanjiv S. Agarwala

Principal Investigators

  • Robert Hans Ingemar Andtbacka

  • Kristen N. Rice

  • Merrick I. Ross

  • Charles Raben Scoggins

  • Bernard Mark Smithers

  • Eric D. Whitman

  • Eric Andrew Wachter

Medical Centers

  • St. Luke's Hospital and Health Network and Temple University, Bethlehem, PA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Medcl Onc Assoc of San Diego, San Diego, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Louisville, Louisville, KY

  • Princess Alexandra Hospital and University of Queensland, Brisbane, Australia

  • Atlantic Melanoma Ctr, Morristown, NJ

  • Provectus Biopharmaceuticals, Inc, Knoxville, TN

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Imlygic

  • Pembrolizumab

  • Temozolomide

  • dacarbazine Intravenous

  • Rose bengal sodium

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02288897

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved